comparemela.com

Latest Breaking News On - Jefferie michael yee - Page 2 : comparemela.com

Why Ventyx Biosciences Zoomed Nearly 60% Higher This Week

The biotech benefits from a much larger peer's recent FDA approval.

Jefferie michael yeeTiago fauthVentyx biosciencesCredit suisseDrug administrationBristol myers squibbBlack box

Hedge Fund M28 Capital Increases Adagio Therapeutics (ADGI) Stake To 8 5%

M28 Capital filed a 13D/A with the US SEC revealing it bought 2.85 million Adagio Therapeutics (NASDAQ:ADGI) at an average of $4.28 per share

Jefferie michael yeeWalter schlossStephen willeyPexels pixabayStoke therapeutics inc bio pharmaHedge fundHow one hedge fundUs securities exchange committeeRocket pharmaceuticals incWave life sciencesIncreases adagio therapeuticsExchange committeeAdagio therapeuticsThree arrows capitalFull walter schloss seriesQualified financial

Biogen at the brink, Pfizer s big bet and other takeaways from a quiet JPM

The banality of Zoom and absence of a big buyout notwithstanding, a flurry of licensing deals kept things interesting.

San franciscoUnited statesSteve rusckowskiDoug braunsteinMichel vounatsoRhonda longmore grundEli lillyJefferie michael yeeAndrew obenshainThomas klimaBristol myers squibbGiovanni caforioNick leschlyGlaxosmithkine shingrixWolfe research tim andersonRock health

Why Adagio Therapeutics Stock Dived by 13% Today

Another analyst gets notably less bullish on the company's prospects.

Jefferie michael yeeMorgan stanleyAdagio therapeutics

vimarsana © 2020. All Rights Reserved.